ArticleBlood2018
Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with
Open access · bronzeAbstract read
In one paragraph
Article in Blood, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
8.3field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 113 citations in OpenAlex.
- Treating relapsed/refractory mature T- and NK-cell neoplasms with tislelizumab: a multicenter open-label phase 2 study.Blood advances · 2023Trial
- From molecular pathogenesis to novel Therapeutic approaches - a review of recent advances in the treatment of peripheral T cell Lymphomas.Biomarker research · 2026Review
- A Novel CD58 Mutation-Related Signature Predicts Prognosis Risk in Diffuse Large B-Cell Lymphoma Patients.Cancer research and treatment · 2026Article
- A phase 1 trial of romidepsin, azacitidine, dexamethasone, and lenalidomide in relapsed or refractory T-cell lymphoma.Blood advances · 2026Article
- Cancer-Testis Antigens in Immuno Oncology Mechanisms Therapeutic Strategies and Clinical Perspectives.Journal of immunology research · 2026Review
- Immunogenic Cell Death-relevant Molecular Patterns, Prognostic Genes, and Implications for Immunotherapy in Ovarian Cancer.Current medicinal chemistry · 2026Article
- ALK-negative anaplastic large cell lymphoma in pediatric and adolescent patients: a mini-review.Frontiers in oncology · 2026Review
- Molecular Insights into the Diagnosis of Anaplastic Large Cell Lymphoma: Beyond Morphology and Immunophenotype.International journal of molecular sciences · 2025Review
- Immunogenic Cell Death-related Signature Evaluates the Tumor Microenvironment and Predicts the Prognosis in Diffuse Large B-Cell Lymphoma.Biochemical genetics · 2025Article
- Advances in peripheral T cell lymphomas: pathogenesis, genetic landscapes and emerging therapeutic targets.Histopathology · 2025Review
- ALK-negative anaplastic large cell lymphoma with TP53 mutation developing during the administration of baricitinib for atopic dermatitis - A case report.Journal of clinical and experimental hematopathology : JCEH · 2025Article
- A practical approach to the modern diagnosis and classification of T- and NK-cell lymphomas.Blood · 2024Review
- Review
- Unveiling the significance of cancer-testis antigens and their implications for immunotherapy in glioma.Discover oncology · 2024Review
- Diagnostic and prognostic molecular pathology of lymphoid malignancies.Virchows Archiv : an international journal of pathology · 2024Review
- Primary cutaneous CD30+ lymphoproliferative disorders with DUSP22 translocation.Pathologie (Heidelberg, Germany) · 2023Review
- Prediction of Tumor Microenvironment Characteristics and Treatment Response in Lung Squamous Cell Carcinoma by Pseudogene OR7E47P-related Immune Genes.Current medical science · 2023Article
- What is new in the classification of peripheral T cell lymphomas?Pathologie (Heidelberg, Germany) · 2023Review
- Pathobiology of nodal peripheral T-cell lymphomas: current understanding and future directions.Haematologica · 2023Review
- Updates in the Classification of T-cell Lymphomas and Lymphoproliferative Disorders.Current hematologic malignancy reports · 2023Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 14 institutions in 6 countries.
Rebecca A LuchtelDepartment of Laboratory Medicine and Pathology and.
Surendra DasariDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN.
Naoki OishiDepartment of Laboratory Medicine and Pathology and.
Martin Bjerregård PedersenDepartment of Hematology, Aarhus University Hospital, Aarhus, Denmark.
Guangzhen HuDepartment of Laboratory Medicine and Pathology and.
Karen L RechDepartment of Laboratory Medicine and Pathology and.
Rhett P KetterlingDepartment of Laboratory Medicine and Pathology and.
Jagmohan SidhuDepartment of Pathology and Laboratory Medicine, United Health Services Hospitals, Johnson City/Binghamton, NY.
Xueju WangDepartment of Pathology, China-Japan Union Hospital of Jilin University, Changchun, China.
Ryohei KatohDepartment of Pathology, University of Yamanashi, Chuo, Yamanashi, Japan.
Ahmet DoganDepartment of Laboratory Medicine and Pathology and.
N Sertac KipDepartment of Laboratory Medicine and Pathology and.
Julie M CunninghamDepartment of Laboratory Medicine and Pathology and.
Zhifu SunDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN.
Saurabh BahetiDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN.
Julie C PorcherDivision of Hematology, Mayo Clinic, Rochester, MN.
Jonathan W SaidDepartment of Pathology, David Geffen School of Medicine, University of California, Los Angeles, CA.
Liuyan JiangDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, FL.
Stephen Jacques Hamilton-DutoitInstitute of Pathology, Aarhus University Hospital, Aarhus, Denmark.ORCID 0000-0003-2158-3885
Michael Boe MøllerDepartment of Pathology, Odense University Hospital, Denmark.ORCID 0000-0003-2041-3630
Peter NørgaardDepartment of Pathology, Herlev Hospital, Herlev, Denmark.
N Nora BennaniDivision of Hematology, Mayo Clinic, Rochester, MN.
Wee-Joo ChngDepartment of Hematology-Oncology, National University Cancer Institute, Singapore.
Gaofeng HuangDepartment of Hematology-Oncology, National University Cancer Institute, Singapore.
Brian K LinkDepartment of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA; and.
Fabio FacchettiDepartment of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.
James R CerhanDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN.
Francesco d'AmoreDepartment of Hematology, Aarhus University Hospital, Aarhus, Denmark.
Stephen M AnsellDivision of Hematology, Mayo Clinic, Rochester, MN.
Andrew L FeldmanDepartment of Laboratory Medicine and Pathology and.ORCID 0000-0001-5009-4808
Mayo Clinic in Florida · USAarhus University Hospital · DKMayo Clinic in Arizona · USUniversity of Yamanashi · JPHerlev Hospital · DKJacksonville College · USNational University Cancer Institute, Singapore · SGNational University of Singapore · SGOdense University Hospital · DKUnion Hospital · CNUnited Health Services · USUniversity of Brescia · ITUniversity of California, Los Angeles · USUniversity of Iowa Hospitals and Clinics · US
Funding
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3MViral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Christopher K Laubenthal · 2000 to 2026
$70.0MThe Role of Monocytes in non-Hodgkin LymphomaP50CA097274 · NCI · UNIVERSITY OF IOWA · PI LENTZ, STEVEN R · 2002 to 2021
$45.7MMayo Clinic Center for Translational Science ActivitiesUL1TR000135 · NCATS · MAYO CLINIC ROCHESTER · PI KHOSLA, SUNDEEP · 2012 to 2015
$41.2MGenetic Biomarkers for Risk Assessment of Peripheral T-Cell LymphomasR01CA177734 · NCI · MAYO CLINIC ROCHESTER · PI FELDMAN, ANDREW LEWIS · 2013 to 2017
$1.6MNCATS NIH HHS UL1 TR000135NCI NIH HHS P30 CA015083NCI NIH HHS P50 CA097274NCI NIH HHS R01 CA177734
Abstract
Anaplastic large cell lymphomas (ALCLs) are CD30-positive T-cell non-Hodgkin lymphomas broadly segregated into ALK-positive and ALK-negative types. Although ALK-positive ALCLs consistently bear rearrangements of the
Indexed as
DNA MethylationGene Expression Regulation, NeoplasticGene RearrangementAntigens, NeoplasmDual-Specificity PhosphatasesFemaleHumansLymphoma, Large-Cell, AnaplasticMaleMiddle AgedMitogen-Activated Protein Kinase PhosphatasesPhosphorylationPrognosisSTAT3 Transcription FactorTranscriptomeTumor EscapeAntigens, NeoplasmDual-Specificity PhosphatasesDUSP22 protein, humanMitogen-Activated Protein Kinase PhosphatasesSTAT3 protein, humanSTAT3 Transcription Factor
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.